JP2009514813A5 - - Google Patents

Download PDF

Info

Publication number
JP2009514813A5
JP2009514813A5 JP2008536725A JP2008536725A JP2009514813A5 JP 2009514813 A5 JP2009514813 A5 JP 2009514813A5 JP 2008536725 A JP2008536725 A JP 2008536725A JP 2008536725 A JP2008536725 A JP 2008536725A JP 2009514813 A5 JP2009514813 A5 JP 2009514813A5
Authority
JP
Japan
Prior art keywords
composition
ligand
antibody
plgf
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008536725A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009514813A (ja
JP5498018B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/040431 external-priority patent/WO2007047609A2/en
Publication of JP2009514813A publication Critical patent/JP2009514813A/ja
Publication of JP2009514813A5 publication Critical patent/JP2009514813A5/ja
Application granted granted Critical
Publication of JP5498018B2 publication Critical patent/JP5498018B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008536725A 2005-10-19 2006-10-16 胎盤成長因子（ＰｌＧＦ）媒介性の転移および／または血管新生の阻害 Expired - Fee Related JP5498018B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72829205P 2005-10-19 2005-10-19
US60/728,292 2005-10-19
PCT/US2006/040431 WO2007047609A2 (en) 2005-10-19 2006-10-16 INHIBITION OF PLACENTA GROWTH FACTOR (PlGF) MEDICATED METASTASIS AND/OR ANGIOGENESIS

Publications (3)

Publication Number Publication Date
JP2009514813A JP2009514813A (ja) 2009-04-09
JP2009514813A5 true JP2009514813A5 (https=) 2009-10-15
JP5498018B2 JP5498018B2 (ja) 2014-05-21

Family

ID=37963183

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008536725A Expired - Fee Related JP5498018B2 (ja) 2005-10-19 2006-10-16 胎盤成長因子（ＰｌＧＦ）媒介性の転移および／または血管新生の阻害

Country Status (8)

Country Link
US (3) US7642239B2 (https=)
EP (1) EP1937724A4 (https=)
JP (1) JP5498018B2 (https=)
KR (1) KR101287280B1 (https=)
CN (2) CN101534865A (https=)
AU (1) AU2006304418B2 (https=)
CA (1) CA2625992C (https=)
WO (1) WO2007047609A2 (https=)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
US8067006B2 (en) * 2005-04-06 2011-11-29 Immunomedics, Inc. Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
US8021646B2 (en) * 2006-12-08 2011-09-20 Northwestern University Compositions and methods for magnetic resonance imaging contrast agents
WO2008151021A1 (en) * 2007-06-01 2008-12-11 Nevada Cancer Institute Isolation and growth of stem cells from hemangiomas
US20080299077A1 (en) * 2007-06-01 2008-12-04 Nevada Cancer Institute Isolation and growth of stem cells from hemangiomas
WO2009080764A2 (en) * 2007-12-20 2009-07-02 Abylnx N.V. Oral or nasal administration of compounds comprising amino acid sequences
US8034396B2 (en) * 2008-04-01 2011-10-11 Tyco Healthcare Group Lp Bioadhesive composition formed using click chemistry
EP2116555A1 (en) * 2008-05-08 2009-11-11 Bayer Schering Pharma Aktiengesellschaft Use of a radioactively labelled molecule specifically binding to ED-B fibronectin in a method of treatment of Hodgkin lymphoma
JP2011520902A (ja) * 2008-05-16 2011-07-21 コーセラ，インコーポレーテッド 創傷の治癒を促進する方法
US8741287B2 (en) * 2008-06-18 2014-06-03 Abbott Laboratories PlGF-1 assay and kits and components thereof
US20100004306A1 (en) * 2008-06-18 2010-01-07 Abbott Laboratories PIGF-1 Assay and kits and components thereof
JP2011525241A (ja) * 2008-06-18 2011-09-15 アボット・ラボラトリーズ ＰｌＧＦ−１コンパニオン診断方法および製品
CA2736929C (en) * 2008-10-02 2019-02-26 Life Sciences Research Partners Vzw Inhibition of plgf to treat philadelphia chromosome positive leukemia
US8940331B2 (en) * 2008-11-22 2015-01-27 The Board Of Trustees Of The Leland Stanford Junior University Hydrogels, methods of making hydrogels, methods of using hydrogels, and methods of isolating, trapping, attracting, and/or killing cancer cells
AU2009329994B2 (en) * 2008-12-23 2014-04-03 Genentech, Inc. Methods and compositions for diagnostic use in cancer patients
EP3912643B8 (en) 2009-02-13 2023-08-23 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
US8968733B2 (en) * 2009-02-21 2015-03-03 Sofradim Production Functionalized surgical adhesives
US8535477B2 (en) 2009-02-21 2013-09-17 Sofradim Production Medical devices incorporating functional adhesives
EP2398584A2 (en) 2009-02-21 2011-12-28 Sofradim Production Apparatus and method of reaching polymers by exposure to uv radiation to produce injectable medical devices
US8877170B2 (en) * 2009-02-21 2014-11-04 Sofradim Production Medical device with inflammatory response-reducing coating
EP2398519A2 (en) 2009-02-21 2011-12-28 Sofradim Production Compounds and medical devices activated with solvophobic linkers
WO2010095045A1 (en) 2009-02-21 2010-08-26 Sofradim Production Amphiphilic compounds and self-assembling compositions made therefrom
EP2398524B1 (en) 2009-02-21 2017-07-12 Covidien LP Medical devices having activated surfaces
US9039979B2 (en) 2009-02-21 2015-05-26 Sofradim Production Apparatus and method of reacting polymers passing through metal ion chelated resin matrix to produce injectable medical devices
US8512728B2 (en) 2009-02-21 2013-08-20 Sofradim Production Method of forming a medical device on biological tissue
US8663689B2 (en) * 2009-02-21 2014-03-04 Sofradim Production Functionalized adhesive medical gel
WO2010095049A1 (en) 2009-02-21 2010-08-26 Sofradim Production Crosslinked fibers and method of making same by extrusion
CA2753188A1 (en) 2009-02-21 2010-08-26 Tyco Healthcare Group Lp Medical devices having activated surfaces
US9523159B2 (en) 2009-02-21 2016-12-20 Covidien Lp Crosslinked fibers and method of making same using UV radiation
WO2010095056A2 (en) 2009-02-21 2010-08-26 Sofradim Production Medical devices with an activated coating
WO2010097800A1 (en) * 2009-02-26 2010-09-02 Muhammad Abdulrazik Synergistic combination of bioactive compounds for lowering of intraocular pressure
ES2978177T3 (es) 2009-12-02 2024-09-06 Immunomedics Inc Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer
US20120259099A1 (en) * 2009-12-15 2012-10-11 MuHyeon CHOE Method for manufacturing dimers and multimers by increasing the production of bond bridges in a complex of multiple monomers and repeating chains of an adherend of a type specifically adhering to monomers
IL205774A0 (en) * 2010-05-13 2010-12-30 Muhammad Abdulrazik Novel compounds for the treatment of glaucoma and ocular hypertension
AU2011231245B2 (en) 2010-03-25 2015-03-26 Covidien Lp Medical devices incorporating functional adhesives
CA2794336A1 (en) * 2010-03-25 2011-09-29 Sofradim Production Surgical fasteners and methods for sealing wounds
CA2804263A1 (en) 2010-06-29 2012-01-12 Tyco Healthcare Group Lp Microwave-powered reactor and method for in situ forming implants
EP2588153A2 (en) 2010-07-01 2013-05-08 Sofradim Production Medical device with predefined activated cellular integration
CN102971422B (zh) * 2010-07-02 2015-07-22 国立大学法人东京农工大学 Psa结合适体和前列腺癌的诊断方法
EP2598178B1 (en) 2010-07-27 2018-07-11 Sofradim Production Polymeric fibers having tissue reactive members
CN102028955A (zh) * 2010-08-09 2011-04-27 华中科技大学同济医学院附属同济医院 一种用于肿瘤基因干预的新型靶向复合物
CN102680619A (zh) * 2011-03-09 2012-09-19 北京康华源医药信息咨询有限公司 一种胶体金属定量检测技术及其用途
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
CN102286101B (zh) * 2011-08-08 2013-05-08 常州亚当生物技术有限公司 抗VEGF单克隆抗体Fab片段Vasculizumab及其应用
WO2013032853A1 (en) 2011-08-26 2013-03-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Activators of cxcr3 for the treatment of angiopathies of the eye
CN102505180A (zh) * 2011-09-16 2012-06-20 彭可扬 一种用于防治室内微生物污染的负载伊曲康唑-溶菌酶电纺纤维膜
ES2628321T3 (es) 2011-12-01 2017-08-02 Thrombogenics N.V. Mejora del resultado de una trabeculectomía
CN103087196B (zh) * 2012-06-26 2016-12-21 青岛大学附属医院 胞壁酰二肽-抗cd20免疫偶联物制备方法及应用
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
SI2900277T1 (sl) * 2012-12-13 2022-05-31 Immunomedics, Inc. Odmerki imunokonjugatov protiteles in SN-38 za boljšo učinkovitost in zmanjšano toksičnost
US9775928B2 (en) 2013-06-18 2017-10-03 Covidien Lp Adhesive barbed filament
EP3094336A4 (en) 2014-01-17 2018-02-14 MIMEDX Group Inc. Method for inducing angiogenesis
US9895419B2 (en) 2014-01-21 2018-02-20 University of Pittsburgh—of the Commonwealth System of Higher Education Goblet cell replacement therapy
WO2015126548A1 (en) 2014-02-21 2015-08-27 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to trop-2 expressing cells
US9139649B2 (en) 2014-02-25 2015-09-22 Immunomedics, Inc. Humanized anti-CD22 antibody
CN104109670B (zh) * 2014-03-12 2018-01-05 首都医科大学附属北京安定医院 一种双链siRNA分子及其应用
TWI625123B (zh) 2014-03-31 2018-06-01 分離胎盤中雌激素之方法
WO2015200260A1 (en) 2014-06-24 2015-12-30 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
CN117138060A (zh) 2014-10-07 2023-12-01 免疫医疗公司 抗体-药物缀合物的新辅助剂用途
KR101551306B1 (ko) * 2015-03-23 2015-09-09 아주대학교산학협력단 뉴로필린1 특이적 결합 펩타이드 및 이 펩타이드가 융합된 융합 단백질, 및 이의 용도
US11000603B2 (en) 2015-04-14 2021-05-11 Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. Multi-specific binding conjugate, related pharmaceutical compositions and use
WO2016172427A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
EP4257134A3 (en) 2015-06-25 2024-01-24 Immunomedics, Inc. Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
PL3316885T3 (pl) 2015-07-01 2021-12-06 Immunomedics, Inc. Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a
CN105669871A (zh) * 2016-04-19 2016-06-15 中国药科大学 一种胸腺肽α1的融合蛋白
CN109195992A (zh) * 2016-04-29 2019-01-11 本康生物制药（深圳）有限公司 多特异性结合偶联物、相关的药物组合物及应用
CN107362370B (zh) * 2016-05-13 2022-07-26 国家纳米科学中心 一种基于金纳米簇联合NGF siRNA治疗胰腺癌的方法
WO2017219974A1 (zh) 2016-06-22 2017-12-28 本康生物制药（深圳）有限公司 用于肿瘤治疗的双特异性抗体和抗体偶联物及其应用
CN106596911B (zh) * 2016-12-16 2019-07-19 石河子大学 一种证明缝隙连接在高血压炎症反应中的作用的试验方法
CN110382550A (zh) 2017-01-24 2019-10-25 本康生物制药（深圳）有限公司 抗体偶联物、相关的药物组合物及应用
JP7560357B2 (ja) * 2017-11-22 2024-10-02 フイルメニツヒ ソシエテ アノニム ランドリーの悪臭、カビの悪臭及び／又は汗の悪臭を調節する組成物を同定する方法
CN110326584B (zh) * 2019-07-04 2020-06-19 西安交通大学 一种p物质诱导的过敏性哮喘动物模型的构建方法和筛选药物的方法
EP4178624A2 (en) 2020-07-07 2023-05-17 Bionecure Therapeutics, Inc. Maytansinoids as adc payloads and their use for the treatment of cancer
US20250073349A1 (en) 2021-05-10 2025-03-06 Kawasaki Institute Of Industrial Promotion Antibody having reduced binding affinity for antigen
CN114404367B (zh) * 2021-12-29 2023-02-21 中山大学附属第一医院 一种通过对病变细胞靶向分布的纳米载体及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686578A (en) * 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
GB9723780D0 (en) 1997-11-12 1998-01-07 Univ Manchester Regulation of ocular angiogenesis
US20040053837A1 (en) 1998-09-30 2004-03-18 Ludwig Institute For Cancer Research Composition and method for modulating vasculogenesis or angiogenesis
EP1179541B1 (en) * 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
US7105168B1 (en) 2002-06-04 2006-09-12 D. Collen Research Foundation Vzw Method of improving ischemic muscle function by administering placental growth factor
US6930089B2 (en) 2000-02-04 2005-08-16 D. Collen Research Foundation Vzw Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic disease or stroke
US7727971B2 (en) 2000-02-04 2010-06-01 Life Sciences Research Partners Vzw Use of placental growth factor for treating ischemic muscle disease
DK2277528T3 (en) 2000-04-12 2015-01-26 Vib Vzw Use of VEGF and homologs for treatment of neuronal diseases
CA2407858C (en) * 2000-05-12 2015-10-27 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage
AU2002241801A1 (en) * 2000-11-07 2002-06-18 Gpc Biotech Inc. Methods and reagents for isolating angiogenic modulators
US20050043227A1 (en) 2001-04-24 2005-02-24 Veerle Compernolle Use of hypoxia inducible factor 2alpha for curing neonatal respiratory distress syndrome and as a target for the treatment of pulmonary hypertension
JP2003012541A (ja) * 2001-06-07 2003-01-15 Daiichi Fine Chemical Co Ltd 血管新生阻害剤
AU2003251728A1 (en) 2002-06-28 2004-01-19 K.U.Leuven Research & Development Placental growth factor as a target for the treatment of osteoporosis
ATE555133T1 (de) * 2003-11-13 2012-05-15 Hanmi Holdings Co Ltd Igg fc fragment für einen arzneimittelträger und verfahren zu dessen herstellung
EP2447281B1 (en) * 2005-03-24 2015-12-16 ThromboGenics N.V. Novel anti-PLGF antibody

Similar Documents

Publication Publication Date Title
JP2009514813A5 (https=)
WO2007047609A2 (en) INHIBITION OF PLACENTA GROWTH FACTOR (PlGF) MEDICATED METASTASIS AND/OR ANGIOGENESIS
Lou et al. Antibody variable region engineering for improving cancer immunotherapy
US10100110B2 (en) Sequences directed against hepatocyte growth factor (HGF) and polypeptides comprising the same for the treatment of cancers and/or tumors
EP2747783B1 (en) Biological materials related to c-met
US9683045B2 (en) Biological materials related to c-Met
CN101868478B (zh) 巨噬细胞刺激蛋白质受体(ron)的抑制及其治疗方法
ES2800330T3 (es) Composiciones que comprenden Anticuerpos anti-IGF-1R y Métodos para obtener dichos Anticuerpos
TWI443109B (zh) 抗ｅｐｈａ２抗體
CN104168914B (zh) Vegf/dll4结合剂及其应用
JP5995851B2 (ja) ＥｒｂＢ３結合抗体
US9346884B2 (en) Biological materials related to c-Met
US8664368B2 (en) Fully human monoclonal antibody to VEGF, preparation method and use thereof
CN102276722B (zh) 新型血管内皮生长因子人源化单克隆抗体
JP7313730B2 (ja) エンドセリン受容体ａ結合力が向上した抗体
CN103965355A (zh) 针对VEGFR2的全人源抗体重链和轻链可变区及相应Fab和全长抗体
CN114685675A (zh) 双特异性抗体及其在治疗癌症中的用途
JP7378088B2 (ja) ｈＥＲＧ１およびｈＥＲＧ１／インテグリンβ１に結合する単一特異性および二重特異性抗体
TWI862564B (zh) 癌治療用醫藥
CN118767131B (zh) 一种热休克蛋白肽制备方法及在恶性肿瘤中的应用
TW202540198A (zh) 雙特異性抗體樣蛋白以及彼之製造及使用方法
JP2026506269A (ja) 組換え抗体及びその用途
CN118660911A (zh) 人间皮素结合剂
HK1199209B (en) Vegf/dll4 binding agents and uses thereof
EA040917B1 (ru) Доставка антител против egfr посредством модульного домена распознавания